Science Advances · 2025 · 23 citations · 61 references
PharmacyImmunologyOncologyDrug DeliveryImmunotherapyNanoparticle Drug DeliveryCancer ImmunotherapyCancer NanomedicineDrug EncapsulationNanocarriers For TherapeuticsNanomedicineTargeted Cancer TherapyCancer Immunotherapy NanoparticlesImmunogenic Cell Death InductionInterferon-stimulated GenesNanocarriersNanoparticle-based ImmunotherapyPd-l1 BlockadeSynergistic Immunotherapy MechanismsTumor-targeted Drug Delivery
The low immunogenicity and immune escape are bottlenecks for effective tumor immunotherapy. Here, we synthesized multifunctional polymers comprising a photosensitizer and cationic and thiol derivates and engineered a galactose-installed stimulator of interferon genes (STING) agonist and programmed death ligand 1 (PD-L1) small interfering RNA (siPDL1)-encapsulated nanocarriers (cGAMP-siPDL1@GalNPs) for synergistic immunotherapy of low immunogenic tumors through stimulating robust immune responses. cGAMP-siPDL1@GalNPs efficiently delivered the drugs into cancer cells by targeting the galactose receptors to trigger photo-/redox-/pH-activated drug release. cGAMP-siPDL1@GalNPs stimulated robust antitumor immunity via STING activation and immunogenic cell death (ICD) and inhibited immune escape via knockdown of PD-L1 expression in tumors, which synergistically regulated the immune-suppressive tumor microenvironment. Upon laser irradiation, the nanocarriers efficiently eradicated primary melanoma and orthotopic triple-negative breast tumors and induced ICD effects, which synergically inhibited the distant tumor and spontaneous lung metastasis with improved survival rates. This study presents a strategy for developing nanocarriers to activate antitumor immunity and regulate immune invasion for effective immunotherapy.
61
Current and future burden of breast cancer: Global statistics for 2020 and 2040
Melina Arnold, Eileen Morgan, Harriet Rumgay et al. · The Breast · 2022 · 3.2K citations · Full text
Cytokines in Cancer Immunotherapy
Sylvia Lee, Kim Margolin · Cancers · 2011 · 683 citations · Full text
Life Sciences, Immunology, Oncology +17
An orally available non-nucleotide STING agonist with antitumor activity
Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux et al. · Science · 2020 · 660 citations